IMPA2

Chr 18

inositol monophosphatase 2

The protein is an inositol monophosphatase that catalyzes the dephosphorylation of inositol monophosphates and other substrates, playing an important role in phosphatidylinositol signaling and serving as a pharmacological target for lithium in the brain. Mutations in this gene cause autosomal recessive developmental and epileptic encephalopathy with microcephaly and cortical malformations, typically presenting in infancy. The gene shows low constraint to loss-of-function variants (pLI = 0.001), consistent with its recessive inheritance pattern.

Summary from RefSeq, UniProt
Research Assistant →
0
Active trials
6
Pubs (1 yr)
93
P/LP submissions
0%
P/LP missense
0.92
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryIMPA2
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
89 unique Pathogenic / Likely Pathogenic· 59 VUS of 166 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.92LOEUF
pLI 0.001
Z-score 1.77
OE 0.49 (0.280.92)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.85Z-score
OE missense 0.82 (0.710.94)
140 obs / 171.3 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.49 (0.280.92)
00.351.4
Missense OE0.82 (0.710.94)
00.61.4
Synonymous OE0.90
01.21.6
LoF obs/exp: 7 / 14.2Missense obs/exp: 140 / 171.3Syn Z: 0.69
DN
0.77top 25%
GOF
0.7127th %ile
LOF
0.2484th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

166 submitted variants in ClinVar

Classification Summary

Pathogenic87
Likely Pathogenic2
VUS59
Likely Benign2
Benign3
87
Pathogenic
2
Likely Pathogenic
59
VUS
2
Likely Benign
3
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
87
0
87
Likely Pathogenic
0
0
2
0
2
VUS
0
46
13
0
59
Likely Benign
0
2
0
0
2
Benign
0
1
2
0
3
Total0491040153

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

IMPA2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →